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Abstract
Genome-wide association studies (GWAS) have been successful in identifying common genetic variation involved in
susceptibility to etiologically complex disease. We conducted a GWAS to identify common genetic variation involved in
susceptibility to upper aero-digestive tract (UADT) cancers. Genome-wide genotyping was carried out using the Illumina
HumanHap300 beadchips in 2,091 UADT cancer cases and 3,513 controls from two large European multi-centre UADT cancer
studies, as well as 4,821 generic controls. The 19 top-ranked variants were investigated further in an additional 6,514 UADT
cancer cases and 7,892 controls of European descent from an additional 13 UADT cancer studies participating in the INHANCE
consortium. Five common variants presented evidence for significant association in the combined analysis (p#561027). Two
novel variants were identified, a 4q21 variant (rs1494961, p = 161028) located near DNA repair related genes HEL308 and
FAM175A (or Abraxas) and a 12q24 variant (rs4767364, p = 261028) located in an extended linkage disequilibrium region that
contains multiple genes including the aldehyde dehydrogenase 2 (ALDH2) gene. Three remaining variants are located in the ADH
gene cluster and were identified previously in a candidate gene study involving some of these samples. The association between
these three variants and UADT cancers was independently replicated in 5,092 UADT cancer cases and 6,794 controls non-
overlapping samples presented here (rs1573496-ADH7, p = 561028; rs1229984-ADH1B, p = 761029; and rs698-ADH1C, p = 0.02).
These results implicate two variants at 4q21 and 12q24 and further highlight three ADH variants in UADT cancer susceptibility.
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Introduction
560,000 cases of upper aerodigestive tract (UADT) cancers
(encompassing of the oral cavity, pharynx, larynx and esophagus)
are estimated to occur each year world-wide [1]. Exposure to
alcohol and tobacco [1] are the major UADT cancer risk factors in
Europe and the Americas, with infection with human papilloma-
virus also playing an important role [2].
Elevated familial relative risks are consistently reported for
UADT cancers [3-7]. While this implies that genetics contributes to
UADT cancer susceptibility, the identity of the specific genes
involved remains unclear. Studies of common genetic variation and
UADT cancer susceptibility have mostly employed a candidate
gene approach, with a particular focus on the genes that metabolize
alcohol [8]. The metabolism of alcohol releases the carcinogen
acetaldehyde as an intermediate [9]. As genetic variation in alcohol
metabolism genes appears to influence their rate of function [10,11],
variants that lead to a relative increase in exposure to acetaldehyde
are expected to confer carriers to an increased risk of UADT
cancers [12]. Consistent with this hypothesis, genetic variation in
the alcohol dehydrogenase (ADH) 1B, and the aldehyde dehydrogenase 2
(ALDH2) genes in Asian populations have been associated with
UADT cancer risk [8,12,13]. Three independent variants ADH1B,
ADH7 and ADH1C variants have also been associated with UADT
cancer risk in European populations [14]. Common genetic
variation in additional genetic pathways have also been considered,
although with some exceptions, such as DNA repair [15,16], the
results have been inconsistent [3].
A Genome-Wide Association Study of UADT Cancers
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The candidate gene based studies have tested only a very small
proportion of common human genetic variation in relation to
UADT cancer risk. To further investigate common genetic
variation and susceptibility to UADT cancers, we have performed
a genome-wide association study within the International Head
and Neck Cancer Epidemiology (INHANCE) consortium, com-
prising genome wide analysis of 2,091 UADT cancer cases and
8,334 controls and replication analysis of the nineteen top ranked
variants in an independent series consisting of 6,514 UADT
cancer cases and 7,892 controls from thirteen additional studies.
Results
Genome-wide results
After exclusion of suboptimal DNA based on QC criteria, data
from 2,091 cases and 3,513 study specific controls and 4,821
generic controls were available for statistical analyses (Table S1)
with 294,620 genetic variants. The overall results did not show a
large deviation from what was expected by chance (l= 1.07)
(Figure 1). One genetic variant, rs971074, was strongly associated
with UADT cancers (p,161028). rs971074 is positioned in the
ADH7 locus on chromosome 4q23 and is highly correlated
(r2 = 1.0 CEU hapmap) with the SNP in ADH7, rs1573496, that
we have described previously to be associated with UADT cancer
risk [14]. Similarly, rs1789924, which is highly correlated
(r2 = 0.97 CEU hapmap) with ADH1C rs698, was also highly
ranked (p = 261026).
Variant selection for replication
For further analysis we selected the twenty top ranked genetic
variants (including rs971074) for replication (Figure S1). These
included those genetic variants in the discovery phase that achieved
a p-value of #161025 (12 variants) as well as nonsynonymous
variants that achieved a p-value of#161024 (5 additional variants).
We also included variants that achieved a p-value of #561027
when restricting the analysis to a specific UADT cancer site (1
variant), or heavy drinkers (1 variant) (Table 1). Only one variant
from each high r2 group (r2.0.8) was included. We additionally
included the non-synonymous ADH1B variant, rs1229984, that has
been previously associated with UADT cancers [14] but not
genotyped or tagged by a proxy variant on the HumanHap300
BeadChip. The association between the top ranked genetic variants
selected for replication and UADT cancer was not sensitive to
adjustment for population structure using principal component
analysis, or exclusion generic controls (Table S2). rs1573496 was
genotyped for replication as a proxy for rs971074 (r2 = 1.00) and
rs698 for rs1789924 (r2.0.97) due to availability of Taqman assays.
A TaqMan assay for rs12827056 could not be designed and no
highly correlated (r2.0.95) proxy genetic variant was available,
hence further investigation was not possible.
Replication and combined results
Five genetic variants at three loci, 4q21, 4q23 and 12q24, were
significantly associated with UADT cancer risk in the replication
series (assuming Bonferroni correction for 19 comparisons or
p#0.003, or p = 0.05 for previously described variants) or in the
combined analysis (p-value of #561027) (Table 1) (Figure S2).
Using imputed genotypes across the 4q21, 4q23 and 12q24
regions based on Caucasian individuals from the HapMap
consortium, we did not identify any variants more strongly
associated with UADT cancer risk than the SNPs genotyped on
the beadchips directly (Figure 2).
Two novel variant loci were identified. rs4767364 located at
12q24 (preplication = 4610
24; pcombined = 2610
28) was one of
Figure 1. Manhattan plot of the ARCAGE and CE UADT cancer GWAS discovery phase. One clearly outlying marker, rs971074 is highly
correlated with rs1573496, a SNP previously associated with UADT cancer risk. Right panel QQ plot for the UADT cancer GWAS.
doi:10.1371/journal.pgen.1001333.g001
Author Summary
We have used a two-phased study approach to identify
common genetic variation involved in susceptibility to
upper aero-digestive tract cancer. Using Illumina Human-
Hap300 beadchips, 2,091 UADT cancer cases and 3,513
controls from two large European multi-centre UADT
cancer studies, as well as 4,821 generic controls, were
genotyped for a panel 317,000 genetic variants that
represent the majority of common genetic in the human
genome. The 19 top-ranked variants were then studied in
an additional series of 6,514 UADT cancer cases and 7,892
controls of European descent from an additional 13 UADT
cancer studies. Five variants were significantly associated
with UADT cancer risk after the completion of both stages,
including three residing within the alcohol dehydrogenase
genes (ADH1B, ADH1C, ADH7) that have been previously
described. Two additional variants were found, one near
the ALDH2 gene and a second variant located in HEL308, a
DNA repair gene. These results implicate two variants 4q21
and 12q24 and further highlight three ADH variants UADT
cancer susceptibility.
A Genome-Wide Association Study of UADT Cancers
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Figure 2. Imputation and LD patterns. Imputation and LD patterns across the (a) 4q23 (ADH loci), (b) 12q24 (ALDH2), and (c) 4q21 (HEL308).
Upper panel: Single marker association results for imputed (green) and directly genotyped variants (blue). Imputation performed on 2,091 cases and
3,513 study specific controls (excluded generic controls). After adjustment for the five variants that presented with replication, no variant had a
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multiple highly correlated SNPs (r2$0.8) that presented evidence
for association in the GWAS stage. It is located in a LD region
including multiple genes including the aldehyde dehydrogenase 2
(ALDH2) (Figure 2), another key gene in alcohol metabolism
(Figure 2). In stratified analysis in the combined 8,744 UADT
cancer cases and 11,982 controls (Table S3), the association was
more pronounced in esophageal cancers compared to other
UADT cancer subsites (p heterogeneity = 0.01) and exhibited
borderline heterogeneity when stratifying by alcohol use (Figure 3).
Some heterogeneity was noted by when stratifying by country
(p = 0.004), although there was no discernable geographic
distribution that could explain this heterogeneity (data not shown).
We noted little evidence for association between alcohol
consumption and rs4767364 (Table 2), nor was there evidence
for any gene-gene interactions between associated variants in ADH
gene cluster and rs4767364 (data not shown).
The second additional locus identified was at 4q21, with the
nonsynonmous variant rs1494961 located in the HEL308 gene
(preplication = 2610
25, pcombined = 1610
28) (Table 1). In combined
analysis, the association tended to be more pronounced in younger
ages and smokers (Figure 4). Given the possible role of the HEL308 in
DNA repair, we also investigated the possibility that rs1494961 may
play a role in lung cancer susceptibility by genotyping rs1494961 in a
series of 5,652 lung cancer cases and 9,338 controls. We noted a
similar association between rs1494961 and lung cancer (OR = 1.09,
p = 361024) from nine lung cancer studies, even when we excluded
1,844 cases and 2,735 controls where controls overlapped with the
central European UADT study (OR = 1.09, p = 0.005).
Replication of ADH genes associations
The association between the ADH variants, rs1573496,
rs1229984 and rs698 at 4q23 and UADT cancer was described
previously [14] in the CE, ARCAGE (excluding Bremen) and SA
studies. When excluding these studies, the association with these
variants was independently replicated in the additional 5,092
UADT cancer cases and 6,794 controls presented here
(p = 561028, 761029 and 0.02 for rs1573496, rs1229984 and
rs698, respectively) (Table 1). We combined all studies totaling
8,744 UADT cancer cases and 11,982 study specific controls to
investigate effects of the ADH variants among different strata
(Figure 3). For both the ADH1B and ADH7 variants heterogeneity
was noted by UADT cancer subsite (p heterogeneity = 0.002, and
0.06 respectively). The rs1229984 ADH1B variant showed strong
heterogeneity when stratifying by alcohol, with little evidence for
association in never drinkers. By contrast, there was little evidence
for heterogeneity noted with rs1573496 and rs698, but a
statistically significant association with the ADH7 variant
rs1573496 was observed never drinkers (p = 0.03).
Among ever drinkers in this pooled analysis, the minor allele
carriers of rs1229984 reported consuming less alcohol than non-
carriers (p = 3610220). rs1573496 minor allele carriers similarly
were noted to consume somewhat less alcohol (p = 0.002), while
rs698 minor allele carriers consumed slightly more (p = 0.05)
(Table 2). Adjustment for alcohol consumption made little
difference to the risk estimates for UADT cancer with all three
variants (Table S4).
Association in African Americans
We additionally genotyped the five variants significantly
associated with UADT cancer in 537 African American UADT
cancer cases and 539 controls noting a significant association for
the 12q24 variant rs4767364 (p = 0.004) (Table 3). Nevertheless,
the smaller sample size and potential differences in genetic
architecture between European and African American populations
(both in terms of allele frequencies and LD structure) limits our
ability to assess these five alleles in African-Americans.
Discussion
Five genetic variants at three loci, 4q23, 12q24 and 4q21, were
significantly associated with UADT cancers in the independent
replication series or after correction for multiple testing at a
genome wide level in combined analysis (p#561027). The risk
effects noted with all five variants were less prominent in the
replication series when compared with the initial finding in the
discovery series, consistent with the notion of ‘‘winner’s curse’’
[17]. In combination we estimate these 5 variants are likely to
explain only a small proportion (approximately 4%) of the UADT
cancer familial risk.
12q24
The 12q24 variant, rs4767364, is positioned in an extended region
of LD that contains multiple genes. Candidate genes include the
aldehyde dehydrogenase 2 (ALDH2) (Figure 2), another key gene in alcohol
metabolism. The minor allele carriers of ALDH2 variants rs737280
and rs4648328, in LD with rs4767364 (r2 = 0.86 and 0.67,
respectively), have been associated with differences in alcohol
metabolism in Europeans, leading some authors to hypothesise [18]
that these alleles have a similar, albeit more modest, effect in European
populations to that of the ALDH2 rs671 variant linked to alcohol
metabolism differences [10] in Asian populations. The increased
UADT cancer risk we observed with the minor allele of rs4767364
(and rs737280 by imputation, Figure 2) is similar to the UADT cancer
risk effect observed for heterozygote rs671 carriers [12,13] and is
consistent with this hypothesis. Nevertheless, this region contains
many additional plausable candidate genes. Other GWAS have
implicated multiple variants in this region in many phenotypes (type 1
diabetes, arthritis, renal function, hemoglobin concentration/hemat-
ocrit, coronary artery disease and waist-to-hip ratio) [19-26] and
therefore the nature of the actual causative allele and gene remains to
be determined. The rs4767364 variant was also associated with
UADT cancer risk in a smaller series of African Americans implying
that this effect may be relevant to other populations.
4q21
The 4q21 variant significantly associated with UADT cancers
was rs1494961 located (Table 1) 20 Mb proximal to the ADH gene
cluster. There is no LD between rs1494961 and either rs1229984,
rs1573496 or rs698 (r2,0.003). rs1494961 is a non-synonymous
variant positioned in the HEL308 gene, a single stranded DNA-
dependent ATPase and DNA helicase involved in DNA intra-
strand cross-linking repair [27], although the residue involved,
I306V, is not an evolutionary conserved site [28] suggesting that
this alteration may not have a functional consequence. rs1494961
is in a LD region spanning approximately 90 kb, and is highly
correlated (r2.0.95) with more than 20 common genetic variants.
This region contains additional genes (Figure 2), notably a second
DNA repair-related gene, FAM175A (or Abraxas and CCDC98),
that interacts directly with the BRCT repeat region of BRCA1
[29]. That a comparable association was noted between this
p,0.0005 at any loci. Lower panel, pairwise LD estimates increasing intensities of black and red indicate higher r2 or D’ statistics, respectively. Blue
colour indicates that the pairwise comparison is not informative.
doi:10.1371/journal.pgen.1001333.g002
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variant and lung cancer (p = 361024) (Figure 4) suggests that the
causal variant maybe relevant for cancers influenced by tobacco
consumption in general.
4q23
The top two ranked variants (rs1573496 and rs698 and
correlated variants) from the GWAS stage we have previously
associated with UADT cancer risk [14]. The association between
these variants, and a third variant, rs1229984, not included in the
Humanhap300 beadchip but genotyped here based on our
previous findings [14], and UADT cancer was independently
replicated in the additional UADT cases and controls presented
here (p = 161027, 161028 and 0.01 for rs1573496, rs1229984
and rs698, respectively).
The combined sample series presented here, totaling 8,774
UADT cancer cases and 11,982 controls, allowed further
Figure 3. Stratified analysis of 4 replicated SNPs located near alcohol metabolism genes. Estimates for rs1229984 (ADH1B), rs1573496
(ADH7), rs1042758 (ADH1C) and rs4767364 (ALDH2) were derived from a log-additive genetic model. ORs were adjusted by age, sex, study and were
derived from fixed effects models. ‘‘Generic’’ controls were not included in this analysis.
doi:10.1371/journal.pgen.1001333.g003
A Genome-Wide Association Study of UADT Cancers
PLoS Genetics | www.plosgenetics.org 7 March 2011 | Volume 7 | Issue 3 | e1001333
Table 2. Association between rs1229984, rs1573496, rs698, rs4767364, and drinking intensity in ever drinkers expressed as mean
of ml of ethanol consumed per day.
All Controls UADT Cases
n mean CI 95% n mean CI 95% n mean CI 95%
rs1229984 (ADH1B) CC 14,518 35.06 33.32–36.80 7,742 22.43 20.91–23.95 6,776 46.76 43.31–50.21
CT,TT 1,323 22.85 18.73–26.98 907 15.60 12.35–18.85 416 23.97 14.68–33.25
p-trend 3610220 5610210 3610212
rs1573496 (ADH7) GG 12,936 35.02 33.21–36.82 6,823 22.36 20.79–23.93 6,113 46.84 43.28–50.40
GC, CC 2,926 30.29 27.36–33.22 1,822 19.68 17.25–22.11 1,104 38.73 32.68–44.78
p-trend 0.002 0.03 0.008
rs698 (ADH1C) TT 5,574 32.05 29.69–34.41 3,054 20.65 18.65–22.66 2,520 42.17 37.48–46.85
TC 6,748 32.51 30.29–34.74 3,685 21.40 19.51–23.29 3,063 42.32 37.91–46.74
CC 2,377 36.15 32.92–39.39 1,285 20.42 17.63–23.22 1,092 51.03 44.74–57.31
p-trend 0.05 0.32 0.06
rs4767364 (ALDH2) GG 7,232 33.78 31.66–35.90 4,114 21.40 19.57–23.22 3,118 45.02 40.81–49.23
AG 6,297 33.91 31.68–36.14 3,302 21.44 19.48–23.40 2,995 45.00 40.65–49.34
AA 1,527 35.84 31.91–39.77 718 25.09 21.43–28.74 809 45.98 38.88–53.09
p-trend 0.60 0.14 0.96
Adjusted mean of ml per day were derived from ANOVA.
P-trend were derived from a linear regression with log(ml of ethanol per day) as an outcome using a log-additive genetic model.
All estimates were adjusted by sex, age, study, pack-years (and case/control status when appropriate).
doi:10.1371/journal.pgen.1001333.t002
Figure 4. Association between 4q21 variant (rs1494961) and UADT and lung cancers. Estimates were derived from a log-additive model.
ORs were adjusted by age, sex, study and were derived from fixed effects models. ‘‘Generic’’ controls were not included in this analysis.
doi:10.1371/journal.pgen.1001333.g004
A Genome-Wide Association Study of UADT Cancers
PLoS Genetics | www.plosgenetics.org 8 March 2011 | Volume 7 | Issue 3 | e1001333
exploration of these genetic effects among UADT cancer subsites
and strata defined by gender, drinking and smoking. The effects of
these three variants were generally present for each UADT sub-
sites but more pronounced in esophageal cancers and males
(Figure 3). Strong heterogeneity was found with rs1229984 when
stratifying by alcohol consumption. Notably, an association was
observed in ‘‘Ever drinkers-Never smokers’’, but not in ‘‘Never
drinkers-Ever smokers’’, suggesting the effect with the rs1229984
variant is mediated through alcohol drinking rather than tobacco
smoking. In contrast, the lack of heterogeneity for rs1573496 when
stratifying by alcohol use may imply differences in the mechanism
of carcinogenesis among these ADH variants.
Several studies have suggested rs1229984 may influence alcohol
consumption behaviour [30-33]. We have strongly replicated this
association (p = 3610220). Similarly, minor allele carriers of
rs1573496 and rs698 also consumed different amounts of alcohol
compared with non-carriers (Table 2). Comparable to the
observations made between 15q25 variants, propensity to smoke
and lung cancer [34-36], adjustment for alcohol consumption did
not fully explain the UADT cancer association with these variants
(Table S4) suggesting, at least within the limits of this measurement
of alcohol consumption, that these risks are unlikely to be
explained by alcohol consumption behaviour patterns.
In conclusion, this study has identified two novel variants
robustly associated with UADT cancers, and independently
replicated three variants previously identified. All five variants
variants are positioned near genes that appear relevant to etiology
of UADT cancers, although further work is needed to identify the
causative allele and gene at these loci.
Materials and Methods
Discovery phase study samples
Genome-wide genotyping was performed in two European
based multi-centre UADT cancer case-control studies (Table 4),
the International Agency for Research on Cancer (IARC) central
europe study [14,37,34] conducted from 2000 to 2002, in 6
centers from 5 countries; and the ARCAGE [14,34,38] (Alcohol-
Related Cancers and Genetic susceptibility in Europe) multicentre
case control study conducted by IARC from 2002 to 2005 in 12
centers from 9 European countries. DNA of sufficient quality and
quantity for genome-wide genotyping was available for 2,230
UADT cancer cases (squamous cell carcinomas) and 4,090
controls from these two studies. We additionally included 4,983
generic controls to further increase statistical power. These generic
controls included: 1,385 individuals from the 1958 birth cohort,
(Wellcome Trust case control consortium[39]) as well as 1,823
French and 433 Norwegian controls genotyped by the Centre
National Genotypage (CNG Evry France). We also included in
our control series a separate group of 1,342 kidney cancer cases
from the same centres as the central Europe study, inclusion or
exclusion of these ‘‘controls’’ had no material effect on the results
presented (Table S2). Both studies have been approved by local
ethics committees as well as IARC IRB.
Genome-wide genotyping and quality control
The central Europe study and the ARCAGE study were
genotyped using the Illumina Sentrix HumanHap300 BeadChip
at the Centre d’Etude du Polymorphisme Humain (CEPH) and
the CNG as described previously [34,40].
We conducted systematic quality control steps on the raw
Illumina HumanHap300 genotyping data. Variants with a
genotype call rate of less than 95% and also individuals where
the overall genotype completion rate was less than 95% were
excluded. We also conducted further exclusions where the
genotype distribution clearly deviated from that expected by
Hardy-Weinberg Equilibrium (HWE) among controls (p-value of
less than 1027) and where there were discrepancies between sex
based genotype and reported sex, as well as individuals with
unlikely heterozygosity rates across genetic variants on the X
chromosome (Table S1). Those genotyped were restricted to
individuals of self – reported European ethnicity. To further
increase the ethnic homogeneity of the series, we used the program
STRUCTURE [41] to identify individuals of mixed ethnicity.
Using a subseries of 12,898 genetic variants from the HumanHap
300 BeadChip panel evenly distributed across the genome and in
low linkage disequilibrium (LD) (r2,0.004) [42], we estimated the
genetic profile of the study participants compared with individuals
of known ethnic origins (the Caucasian, African and east-Asian
individuals genotyped by the HapMap project). We excluded 34
individuals because of some evidence of ethnic admixture (Figure
S3), indicating that the extent of admixture within the central
Europe and ARCAGE study centers is limited.
Genome-wide statistical analysis
The association between each genetic variant and the disease
risk was estimated by the odds ratio (OR) per allele and ninety-five
percent confidence intervals (CI) using multivariate unconditional
logistic regression assuming a log-additive genetic model with sex
and country of recruitment included in the regression model as
covariates. Results that obtained a level of significance of a two
sided p,561027 were considered significant at a genome wide
Table 3. Comparison of results from the genome-wide analysis with analysis in a UADT case-control series of African-American
origin.
Marker
Combined GWA and replication
analysis (European descent) African American
MAF OR 95% CI p-value MAF Ca/Co OR 95% CI p-value
rs1229984 (ADH1B) 0.06 0.64 0.59–0.71 1610220 0.03 532/546 0.99 0.46–2.13 0.98
rs1573496 (ADH7) 0.11 0.75 0.70–0.80 9610217 0.02 536/547 0.83 0.37–1.89 0.66
rs698 (ADH1C) 0.38 1.12 1.07–1.17 361027 0.18 508/527 1.10 0.87–1.39 0.44
rs4767364 (ALDH2) 0.29 1.13 1.08–1.18 261028 0.45 537/539 1.35 1.10–1.65 461023
rs1494961 (HEL308) 0.49 1.12 1.08–1.17 161028 0.26 544/540 1.06 0.88–1.29 0.53
Ca: number of cases; Co: number of controls.
MAF: minor allele frequency in controls.
doi:10.1371/journal.pgen.1001333.t003
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level [39]. All analyses were conducted using PLINK [43]. We also
conducted analyses restricting to UADT cancer subtypes (oral/
pharyngeal cancer, laryngeal cancer, esophageal cancer) and
restricting to heavy (.median) drinkers and heavy (.median)
smokers.
The potential for population stratification not accounted for by
adjustment by country was also investigated by principal
components analysis (PCA) undertaken with the EIGENSTRAT
package [44] using 12,898 markers in low LD [42]. Adjustment for
population stratification using the PCA was performed by
including significant eigenvectors that were associated with case
control status (p,0.05) as covariates in the logistic regression.
Genotypes for genetic variants across 4q21, 4q23 and 12q21 not
genotyped on the Illumina HumanHap300 BeadChip, but
genotyped by the HAPMAP consortium, were imputed using
the program MACH with phased genotypes from the CEU
Hapmap genotyping as a scaffold. Unconditional logistic regres-
sion using posterior haplotype probabilities (haplotype dosages)
from MACH were carried out using ProbABEL [45] including
age, sex, and country of origin in the regression as covariates.
Linkage Disequilibirum (LD) statistics (D’ and r2) were calculated
using Haploview [46].
Replication study samples
The replication series consisted of 6,514 UADT cancer cases
(squamous cell carcinomas) and 7,892 controls from 13 UADT
cancer case-control studies (Table 4). With the exception of the
Szczecin case-control study [16], all studies were part of the
Table 4. The 15 UADT cancer studies participating in the genome-wide and replication analysis.
Study Name Study setting
Coordinating
centre
Genotyping
centre
Principal
Investigators
UADT
Subsitese
Control
source Casesa Controlsa Cases Controls
GWAS Post GWAS Qc
ARCAGE b Europe -
Multicentre
IARC CNG Boffetta/
Brennan
UADT Hospital-based 1,422 1,503 1,368 1,313
Central Europe c Europe -
Multicentre
IARC CNG Boffetta/
Brennan
UADT Hospital-based 808 2,587 723 2,200
Generic controls 4,821
Replication
SAd Latin America -
Multicentre
IARC IARC Boffetta/
Brennan
UADT Hospital-based 1,422 1,098
ARCAGE -
Bremen
Bremen -
Germany
Bremen Uni. IARC Ahrens UADT Hospital-based 164 190
Rome Roma - Italy Uni. Rome IARC Boccia HN Hospital-based 251 237
Poland Szczecin -
Poland
Szczecin Uni IARC Lubinski Larynx Hospital-based 409 1,039
Seattle
(Oral Gen study)
Washington-
US
Fred Hutchinson
Cancer Research
Centre
FHCRC Schwartz
/Chen
HN Population-based 193 388
University of
North Carolina
(CHANCE study)
North Carolina -
US
University of
North Carolina
University
of North
Carolina
Olshan HN Population-based 940 1,087
Penn State Tampa - US Penn State
University
Penn State
University
Muscat/
Lazarus
Hospital-based 310 534
Philadelphia, New
York City - US
Lazarus HN
UCLA Los Angeles - US University of
California, LA
University of
California, LA
Zhang UADT Population-based 206 577
MD Anderson Houston - US MD Anderson
Cancer Centre
MD Anderson
Cancer Centre
Wei/Sturgis HN Hospital-based 431 431
IARC - oral
cancer (ORC)
Europe -
Multicentre
IARC IARC Franceschi Oral Hospital-based 611 643
Boston (HNSCC) Boston - US Brown Uni. Brown Uni. Kelsey HN Population-based 513 593
University of
Pittsburgh
(SCCHN-SPORE)
Pittsburgh - US University of
Pittsburgh
IARC Romkes HN Hospital-based 610 771
The Netherlands Maastricht
Hospital -
Netherlands
University St
Radboud
Lacko/Peters HN Hospital-based 454 304
Total 8,744 11,982
a Including only individuals of self-reported European ancestry.
b Includes countries: Czech Republic, Greece, Italy, Norway, UK, Spain, Croatia, Germany, France.
c Includes countries: Romania, Poland, Russia, Slovakia, Czech Republic.
d For the three variants at 4q23, results have been published previously, in ‘‘replication’’ analysis for these variants, the SA study was excluded.
e UADT –Oral, pharynx, laryngeal, esophageal cancers, HN – Head and neck cancers Oral, pharynx, laryngeal cancers.
doi:10.1371/journal.pgen.1001333.t004
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INHANCE consortium. As previously described [1,3,47], all
INHANCE studies have extensive information on tumor site and
histology, as well as lifestyle characteristics. The Szczecin, Seattle,
UCLA and MD Anderson studies were only able to genotype a
proportion of the variants (Table S5). Results for the three ADH
variants, rs1229984, rs1573496 and rs698 have been published
previously for the Latin American study (LA). For these variants,
in ‘‘replication’’ analysis the Latin American study was excluded.
All studies have been approved by local ethics committees as well
as IARC IRB.
Replication genotyping
Replication genotyping was performed using the TaqMan
genotyping platform in 8 participating genotyping laboratories
(Table 4). The robustness of the Taqman assays (primers and
probes are available upon request) were confirmed at IARC by re-
genotyping the CEPH HapMap (CEU) trios and confirming
concordance with HapMap genotypes. Any discordance between
Hapmap and Taqman generated genotypes was resolved by direct
DNA sequencing. All Taqman assays were found to be performing
robustly. IARC supplied Taqman assays and a standardized
Taqman genotyping protocol to each of the 8 participating
genotyping laboratories. A common series of 90 standard DNAs
were genotyped at each laboratory to ensure the quality and
comparability of the genotyping results across the different studies.
Concordance with the consensus genotype and the results
produced at the eight genotyping laboratories for the standardized
DNAs was 99.75%, and no individual centre had a overall
concordance of less than 99.5%. If the assay produced 2 or more
discordant genotypes relative to the consensus, the study genotypes
for this genetic variant were not included in the statistical analysis.
Assays that had a per-centre success rate of ,90% or for which
genotype distributions deviated from HWE (p,0.001) were also
excluded (Table S5).
Replication statistical analysis
The association between the nineteen variants and UADT
cancer risk was estimated by per allele ORs and their 95% CI
derived from multivariate unconditional logistic regression, with
age, sex, and study (and country of origin where appropriate)
included in the regression model as covariates. Measures of alcohol
consumption have been previously harmonized across INHANCE
studies [48]. The association between ADH/ALDH2 variants and
alcohol consumption was carried out in ever drinkers using
multivariate linear regression using a log transformed milliliter of
ethanol consumed per day as an outcome, adjusting for age, sex,
study, packyears (and case-control status when appropriate).
Milliliters of ethanol consumed per day was not available for 3
studies (Szczecin, Philadelphia/New York and The Netherlands
study). Heterogeneity of ORs across the studies and across the
stratification groups was assessed using the Cochran’s Q-test. All
replication and combined analyses were conducted using SAS 9.1
software. P values were two sided.
Investigation of the effects of 4q21 variant rs1494961
and lung cancer risk
The series of lung cancer cases and controls used to investigate
4q21 variant, rs1494961, and lung cancer risk included studies
from central Europe (IARC), Toronto (McGill), HUNT2/
Tromso, the CARET cohort, EPIC-lung, the Szczecin case-
control study, Liverpool Lung Project (LLP), Paris France and
Estonia as described previously [34,40,49]. All studies have been
approved by local ethics committees as well as IARC IRB.
Genotyping protocol for 4q21 variant, rs1494961
Genotyping for rs1494691 was performed using the Illumina
beadchips (Central Europe (IARC), Toronto (McGill), HUNT2/
Tromso, the CARET cohort, France and Estonia) or the Applied
Biosystems Taqman assays (EPIC-lung, the Szczecin case-control
study, Liverpool Lung Project (LLP)) at IARC.
For the central European lung cancer study, the controls
overlapped with the central European UADT cancer study for
Bucharest (Romania), Lodz (Poland), Moscow (Russia), Banska
Bystrika (Slovakia), and Olomouc and Prague (Czech Republic).
We therefore performed analyses both including and excluding
centres where controls overlapped.
Web resources
http://inhance.iarc.fr/ (December 2010)
http://www.hapmap.org (December 2010)
http://www.sph.umich.edu/csg/abecasis/mach/index.html
(December 2010)
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